Asia stocks rise as Dec rate cut bets resurface; China lags on chipmaker losses
Investing.com -- Evaxion Biotech AS (NASDAQ:EVAX) stock surged 10.6% on Thursday after the clinical-stage TechBio company announced significant progress in its cytomegalovirus (CMV) vaccine program, EVX-V1.
The Denmark-based company reported that its AI-Immunology™ platform has discovered novel CMV antigens that significantly reduce viral infection in preclinical models. These newly identified antigens, which were previously unexplored in CMV vaccine research, have demonstrated the ability to induce specific immune responses, inhibit viral infection, and reduce cell-to-cell spread in cellular and animal viral infection models.
Evaxion’s EVX-V1 program combines these AI-discovered antigens with AI-optimized versions of established CMV vaccine antigens. The company’s proprietary AI-optimized pre-fusion glycoprotein B (gB) antigen has shown superior performance compared to traditional gB antigens, including enhanced CMV neutralization.
"We are very excited by the new data demonstrating the unique capability of AI-Immunology™ to find novel protective vaccine targets where no others have been able to do so," said Birgitte Rønø, CSO and interim CEO of Evaxion.
The company continues to advance the EVX-V1 program preclinically with further identification, investigation, and optimization of antigens. Simultaneously, Evaxion is exploring strategic partnerships to accelerate development and ensure a smooth transition into non-clinical and clinical phases.
CMV remains an area of significant unmet medical need, with no approved vaccines despite decades of research. Evaxion’s multi-targeted strategy aims to strengthen the protective potential of its future vaccine by attacking the virus from multiple, complementary angles.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.